Skip to main content

Solid Biosciences Inc 10-Q for FY2026 Q3

Solid Biosciences Inc. (SLDB)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Solid Biosciences Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Solid dosed SGT-003 in Phase 3 IMPACT DUCHENNE in April 2026 and scheduled an FDA Type C meeting. Its $348.9 million in cash and securities is expected to fund operations into the first half of 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$53.95M
compared with a net loss of $45.78M a year earlier
Diluted EPS
-$0.36
compared with -$0.48 a year earlier